Table 2. Metabolic parameters in protocol 2: Treatment with inhibitors of RAS or NF-κB activationa

GroupnGlucose (mmol/L)Body Weight (g; Mean ± SD)Kidney Weight (g)Urine Volume (ml/24 h; Mean ± SD)Blood Pressure (mm Hg)AERb (mg/24 h)Glomerulosclerotic IndexTubulointerstitial Area (%)
a Data are shown as mean ± SEM. PDTC, pyrrolidone dithiocarbamate.
b Shown as geometric mean ×/÷ tolerance factor.
c P < 0.0001 versus control.
d P < 0.005 versus control.
e P < 0.01 versus diabetes.
f P < 0.05 versus control.
g P < 0.05 versus diabetes.
h P < 0.02 versus control.
Control86.4 ± 0.2410 ± 171.55 ± 0.0416 ± 1126 ± 30.28 ×/÷ 1.31.3 ± 0.32.1 ± 0.1
Diabetes827.5 ± 0.5c280 ± 9c1.82 ± 0.06d134 ± 8c152 ± 5c0.92 ×/÷ 1.1c1.2 ± 0.33.0 ± 0.2h
D + Valsartan830.6 ± 0.3c290 ± 10c1.56 ± 0.07e157 ± 9c137 ± 3e0.75 ×/÷ 1.1d0.9 ± 0.2eh1.6 ± 0.2ef
D + PD123319829.1 ± 0.7c270 ± 9c1.72 ± 0.09f135 ± 14c140 ± 3fg1.09 ×/÷ 1.1c1.5 ± 0.22.7 ± 0.1f
D + PDTC830.4 ± 1.3c278 ± 9c1.57 ± 0.06e199 ± 11ce124 ± 4e1.16 ×/÷ 1.1c1.1 ± 0.12.1 ± 0.2e